(DXD) |
| 0 (0%) 02-26 15:22 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 20.23 |
| Resistance 1: | 19.61 |
| Pivot price: | 19.35 |
| Support 1: | 18.62 |
| Support 2: | 15.49 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 05 Feb 2026
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC - CancerNetwork
Tue, 03 Feb 2026
FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy - OncLive
Tue, 16 Dec 2025
Which Data in 2026 May Answer Big Questions About Breast Cancer Treatment After T-DXd? - Oncology News Central
Mon, 15 Dec 2025
HER2-Positive Breast Cancer: FDA Approves T-DXd Plus Pertuzumab - The ASCO Post
Mon, 15 Dec 2025
FDA Approves T-DXd Plus Pertuzumab for HER2+ Breast Cancer - OncLive
Wed, 10 Dec 2025
How Do Experts Think Dato-DXd Should Be Used in NSCLC? - CancerNetwork
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
